Newsroom

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Media Center

All
Media Highlights
Press Releases
Media

Scribe’s Genetic Editing Aims to Prevent Heart Attacks

July 27, 2026

Barron's

Read Now
Media

Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds

July 24, 2026

Fierce Biotech

Read Now
Media

Eli Lilly-Backed Scribe Therapeutics Soars 44% After IPO

July 24, 2026

Bloomberg News

Read Now
Media

Scribe Bets on a New Era of Gene Editing

July 24, 2026

Bloomberg Tech

Read Now
Media

Scribe prices upsized IPO before producing human efficacy data

July 24, 2026

Axios

Read Now
Media

CRISPR Biotech Scribe Therapeutics Writes a New Chapter With $129M IPO

July 24, 2026

MedCity News

Read Now
Press release

Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect

July 15, 2022

Read Now
Press release

Scribe Therapeutics Expands Collaboration With Biogen to Second Target

May 2, 2022

Read Now
Press release

Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference

April 1, 2022

Read Now
Press release

Scribe Therapeutics Appoints David Parrot as Chief Financial Officer and George Manning as Controller

March 9, 2022

Read Now
Press release

Scribe Therapeutics Raises $100M Series B Financing to Further Develop 'CRISPR by Design' Platform and Pipeline of Breakthrough Genetic Medicines

March 31, 2021

Read Now
Press release

Scribe Therapeutics Co-Founder Jennifer Doudna Receives 2020 Nobel Prize in Chemistry

October 9, 2020

Read Now

Publications